Recent trends in next generation immunoinformatics harnessed for universal coronavirus vaccine design

Pathog Glob Health. 2023 Mar;117(2):134-151. doi: 10.1080/20477724.2022.2072456. Epub 2022 May 12.

Abstract

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has globally devastated public health, the economies of many countries and quality of life universally. The recent emergence of immune-escaped variants and scenario of vaccinated individuals being infected has raised the global concerns about the effectiveness of the current available vaccines in transmission control and disease prevention. Given the high rate mutation of SARS-CoV-2, an efficacious vaccine targeting against multiple variants that contains virus-specific epitopes is desperately needed. An immunoinformatics approach is gaining traction in vaccine design and development due to the significant reduction in time and cost of immunogenicity studies and increasing reliability of the generated results. It can underpin the development of novel therapeutic methods and accelerate the design and production of peptide vaccines for infectious diseases. Structural proteins, particularly spike protein (S), along with other proteins have been studied intensively as promising coronavirus vaccine targets. Numbers of promising online immunological databases, tools and web servers have widely been employed for the design and development of next generation COVID-19 vaccines. This review highlights the role of immunoinformatics in identifying immunogenic peptides as potential vaccine targets, involving databases, and prediction and characterization of epitopes which can be harnessed for designing future coronavirus vaccines.

Keywords: Human coronavirus; characterization; database; epitope prediction; immunoinformatics; peptide vaccine; vaccine target.

Publication types

  • Review

MeSH terms

  • COVID-19 Vaccines
  • COVID-19*
  • Epitopes, B-Lymphocyte
  • Epitopes, T-Lymphocyte
  • Humans
  • Molecular Docking Simulation
  • Quality of Life
  • Reproducibility of Results
  • SARS-CoV-2
  • Viral Vaccines* / chemistry
  • Viral Vaccines* / genetics

Substances

  • COVID-19 Vaccines
  • Viral Vaccines
  • Epitopes, B-Lymphocyte
  • Epitopes, T-Lymphocyte

Grants and funding

This work was supported by the Malaysia Ministry of Higher Education [203.CIPPM.6711968]; Malaysia Ministry of Higher Education [203/PPSP/6171200]; Universiti Sains Malaysia [1001.CIPPM.8011078].